scholarly journals 1927 nm Thulium Laser Successfully Treats PostInflammatory Hyperpigmentation in Skin of Color

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Mana Abdullah Alharbi
Keyword(s):  
Laser Treatment ◽  
Low Energy ◽  
Body Parts ◽  
Efficacy And Safety ◽  
Thulium Laser ◽  
Dark Skin ◽  
Type Iv ◽  
Postinflammatory Hyperpigmentation ◽  
Darker Skin Types

Background. Treatment of postinflammatory hyperpigmentation (PIH) in patients with dark skin is challenging as the treatment itself might provoke paradoxical PIH. Only few studies examined the safety and efficacy of nonablative laser treatment in these patients. The objective was to examine efficacy and safety of nonablative 1927 nm wavelength laser followed by bleaching creams in the treatment of PIH. Methods. It was a prospective interventional pilot study that was conducted during 2019. All patients were of Fitzpatrick skin type IV who had unsatisfactory response to topical bleaching creams used for at least three months. Patients received one to four sessions of laser treatment (6 weeks apart) followed by topical hydroquinone 4% cream twice daily for 6 weeks. Improvement was assessed by two blinded independent dermatologist evaluators. Results. A total of nine patients were enrolled and the outcome could not be assessed in one patient who was lost for follow-up. The affected sites were the abdomen, face, and other body parts. Three of the eight evaluated patients had excellent response (37.5%), four had satisfactory response (50.0%), and one had nonsatisfactory response (12.5%). The downtime was manifested as edema and erythema that disappeared after 5 to 7 days. Improvement was more evident in first session and it declined in subsequent sessions. None of the patients had paradoxical pigmentation after treatment. Conclusions. Low energy low density nonablative fractional 1927 nm wavelength laser treatment followed by topical hydroquinone 4% cream for 6 weeks is a safe and effective modality for improving PIH in patients with darker skin types.

Assessment of efficacy and safety of micropulse diode laser treatment in glaucoma: One year follow-up

2020 ◽  
Vol 95 (7) ◽  
pp. 327-333
Author(s):  
C. Logioco ◽  
L.D. Perrone ◽  
D. Caruso ◽  
R. Albertazzi ◽  
G. Valvecchia ◽  
...  
Keyword(s):  
Laser Treatment ◽  
Diode Laser ◽  
Efficacy And Safety ◽  
One Year

scholarly journals Hair removal treatment using 1,064 nm long-pulsed Nd:YAG laser in auricular post reconstruction of microtia patient: two case reports

2019 ◽  
Author(s):  
Kartika Ruchiatan ◽  
Erika Dewi Essary ◽  
Reti Hindritiani ◽  
RM Rendy Ariezal Effendi ◽  
Rani Septrina ◽  
...  
Keyword(s):  
Nd:Yag Laser ◽  
Hair Growth ◽  
Case Reports ◽  
Skin Type ◽  
Minimal Risk ◽  
Optimal Result ◽  
Dark Skin ◽  
Type Iv ◽  
Degrees Of Severity

Microtia is a congenital anomaly of the external and middle ear with various degrees of severity. The hair growth on the reconstructed auricle causes aesthetic problems. We describe two cases about the successful epilation of unwanted hair in postauricular reconstruction of microtia patients using 1,064 nm long-pulsed neodymium: ytrium-alumunium-garnet (LP Nd:YAG) laser in Fitzpatrick skin type IV patients, using 6x6 mm tip, 35 J/cm2 fluence, 10 ms pulse, and 1 Hz frequency with burnt of hair as an endpoint. On the follow up day 11 of case one and day 7 of case two, the hair reductions on treated auricles were 46% and 58%, respectively, with no adverse effects. Minimal 6 repeated sessions are recommended for optimal result. In these case reports, LP Nd:YAG laser treatment is considered effective for the unwanted hair growth on the reconstructed auricle in dark skin type patients with minimal risk of adverse effect.

scholarly journals Efficacy and Safety of Diphenylcyclopropenone in the Treatment of Multiple Warts - A Prospective Study at a Tertiary Care Hospital, Mumbai

2021 ◽  
Vol 8 (20) ◽  
pp. 1580-1585
Author(s):  
Prathyusha Yakkala ◽  
Rachita Dhurat ◽  
Meghana Phiske
Keyword(s):  
Prospective Study ◽  
Tertiary Care ◽  
Care Hospital ◽  
Efficacy And Safety ◽  
Viral Origin ◽  
Factors Affecting ◽  
Type Iv ◽  
Significant Difference ◽  
A Prospective Study

BACKGROUND Diphenylcyclopropenone (DPCP) produces type IV hypersensitivity reaction, immune response being directed against a complex of contact agent hapten bound to proteins of viral origin that enhance wart regression. We wanted to evaluate the efficacy and safety of DPCP in multiple warts along with the various factors affecting DPCP response METHODS A prospective study with 49 patients older than 5 years with 5 or more warts in any area (except genital) was conducted. Patients were sensitized with 2 % DPCP solution and examined after 48 hours. Sensitization was graded as mild, moderate, severe or no sensitization. Patients with mild / moderate sensitization were further applied DPCP; patients with severe sensitization were included after subsidence of reaction and patients with no sensitization were excluded. After sensitization, weekly applications were made on warts. Concentration causing mild reaction was selected as optimal and was applied till lesion clearance. Follow up was for 3 months for recurrences. Response was graded as complete, partial and no response. RESULTS Males outnumbered females. Mean age was 23 years. Mean duration was 12 months. Recurrent and resistant warts were seen in 15 and 6 patients respectively. Mean number of warts was 15.6. 49 patients were tested for sensitization, 1 failed sensitization and 48 were continued with weekly DPCP. 2 developed distant eczematisation and 4 were lost to follow up. Out of 42, complete clearance was seen in 35 (83.3 %), partial in 3 (7.14 %) and no response in 4 (9.52 %). Local eczematisation, lymphadenopathy, hyperpigmentation were the side effects. Response was better with increasing age. Warts less than 6 months had 100 % response. There was no statistically significant difference between site and type of warts and response to DPCP, recurrent and untreated warts in terms of response and response to sensitization and final response. CONCLUSIONS DPCP is an excellent option for multiple / resistant warts with good safety profile. KEYWORDS Diphenylcyclopropenone, Multiple Warts, Safety, Efficacy, Various Factors Affecting Response

scholarly journals Comparison of efficacy and safety of the combined laser treatment technology versus conventional laser photocoagulation in diabetic macular edema management

2017 ◽  
Vol 20 (1) ◽  
pp. 68-74
Author(s):  
Aleksander Victorovich Doga ◽  
Galina Fedorovna Kachalina ◽  
Elena Konstantinovna Pedanova ◽  
Dmitry Anatolievich Buryakov
Keyword(s):  
Laser Treatment ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Diabetic Macular Oedema ◽  
Control Group ◽  
Efficacy And Safety ◽  
Treatment Technology ◽  
The Mean ◽  
Conventional Laser

Aim. To evaluate the efficacy and safety of the novel combined laser treatment technology compared with those of the conventional laser photocoagulation in diabetic macular oedema management. Material and methods. Fifty eyes of 44 patients with clinically significant diabetic macular oedema were enrolled. Patients of the main group (25 eyes) underwent combined laser treatment, whereas patients in the control group (25 eyes) underwent modified ETDRS (mETDRS) focal/grid photocoagulation. Results. Mean central point thickness (CPT) in the main group decreased from 411.24 126 m to 359.86 120.4 m (p 0.05), with a subsequent increase in the mean best-corrected visual acuity (BCVA) from 0.52 0.2 at baseline to 0.71 0.2 (p 0.05) at the 12-month follow-up. The mean central retinal sensitivity (RS) improved from 11.27 3.8 dB to 13.24 3.2 dB (p 0.05). In the control group, our results showed similar improvement in BCVA and CPT values at the 12-month follow-up (from 0.59 0.12 to 0.72 0.23 and from 424.17 68.12 m to 387.51 93.45 m, respectively, p 0.05). The RS value, on the contrary, decreased from 12.32 0.90 dB to 10.14 0.71 dB (p 0.05). Conclusions. The combined laser technology is a safe treatment technique that allows to minimise the extent of laser-induced chorioretinal complex damage due to the contribution of subthreshold micropulse laser photocoagulation. The efficacy of this novel technology is comparable with that of the mETDRS technique in the resolution of macular oedema and BCVA increase. This technology also provides an advantage of RS improvement and the possibility of safe and repetitive treatment sessions.

Treatment of varicose tributaries with sclerotherapy with polidocanol 0.5 % foam

VASA ◽  
2010 ◽  
Vol 39 (2) ◽  
pp. 169-174 ◽  
Author(s):  
Reich-Schupke ◽  
Weyer ◽  
Altmeyer ◽  
Stücker
Keyword(s):  
Scientific Evidence ◽  
Daily Practice ◽  
Severe Adverse Effect ◽  
Safe Procedure ◽  
Efficacy And Safety ◽  
Foam Sclerotherapy ◽  
History Of ◽  
One Year ◽  
Additional Therapy

Background: Although foam sclerotherapy of varicose tributaries is common in daily practice, scientific evidence for the optimal sclerosant-concentration and session-frequency is still low. This study aimed to increase the knowledge on foam sclerotherapy of varicose tributaries and to evaluate the efficacy and safety of foam sclerotherapy with 0.5 % polidocanol in tributaries with 3-6 mm in diameter. Patients and methods: Analysis of 110 legs in 76 patients. Injections were given every second or third day. A maximum of 1 injection / leg and a volume of 2ml / injection were administered per session. Controls were performed approximately 6 months and 12 months after the start of therapy. Results: 110 legs (CEAP C2-C4) were followed up for a period of 14.2 ± 4.2 months. Reflux was eliminated after 3.4 ± 2.7 injections per leg. Insufficient tributaries were detected in 23.2 % after 6.2 ± 0.9 months and in 48.2 % after 14.2 ± 4.2 months, respectively. Only 30.9 % (34 / 110) of the legs required additional therapy. In 6.4 % vein surgery was performed, in 24.5 % similar sclerotherapy was repeated. Significantly fewer sclerotherapy-sessions were required compared to the initial treatment (mean: 2.3 ± 1.4, p = 0.0054). During the whole study period thrombophlebitis (8.2 %), hyperpigmentation (14.5 %), induration in the treated region (9.1 %), pain in the treated leg (7.3 %) and migraine (0.9 %) occurred. One patient with a history of thrombosis developed thrombosis of a muscle vein (0.9 %). After one year there were just hyperpigmentation (8.2 %) and induration (1.8 %) left. No severe adverse effect occurred. Conclusions: Foam sclerotherapy with injections of 0.5 % polidocanol every 2nd or 3rd day, is a safe procedure for varicose tributaries. The evaluation of efficacy is difficult, as it can hardly be said whether the detected tributaries in the controls are recurrent veins or have recently developed in the follow-up period. The low number of retreated legs indicates a high efficacy and satisfaction of the patients.

Efficacy and safety of long-acting pasireotide in acromegalic patients in the real life: The reappraisal of the first-dose follow-up visit

2020 ◽  
Author(s):  
Claudio Urbani ◽  
Francesca Dassie ◽  
Benedetta Zampetti ◽  
Di Certo Agostino Maria ◽  
Renato Cozzi ◽  
...  
Keyword(s):  
Real Life ◽  
Efficacy And Safety ◽  
The Real ◽  
Long Acting

scholarly journals Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta

2021 ◽  
Author(s):  
Jon Havelock ◽  
Anna-Karina Aaris Henningsen ◽  
Bernadette Mannaerts ◽  
Joan-Carles Arce ◽  
Keyword(s):  
Ovarian Stimulation ◽  
Implantation Rate ◽  
Neonatal Outcomes ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Relative Contribution ◽  
Follitropin Alfa ◽  
Start Up ◽  
Comparative Trials

Abstract Purpose To describe the pregnancy and neonatal outcomes using fresh and vitrified/warmed blastocysts obtained from ovarian stimulation with follitropin delta in controlled trials versus follitropin alfa. Methods This investigation evaluated the outcome from 2719 fresh and frozen cycles performed in 1326 IVF/ICSI patients who could start up to three ovarian stimulations in the ESTHER-1 (NCT01956110) and ESTHER-2 (NCT01956123) trials, covering 1012 fresh cycles and 341 frozen cycles with follitropin delta and 1015 fresh cycles and 351 frozen cycles with follitropin alfa. Of the 1326 first cycle patients, 513 continued to cycle 2 and 188 to cycle 3, and 441 patients started frozen cycles after the fresh cycles. Pregnancy follow-up was continued until 4 weeks after birth. Results The overall cumulative take-home baby rate after up to three stimulation cycles was 60.3% with follitropin delta and 60.7% with follitropin alfa (−0.2% [95% CI: −5.4%; 5.0%]), of which the relative contribution was 72.8% from fresh cycles and 27.2% from frozen cycles in each treatment group. Across the fresh cycles, the ongoing implantation rate was 32.1% for follitropin delta and 32.1% for follitropin alfa, while it was 27.6% and 27.8%, respectively, for the frozen cycles. Major congenital anomalies among the live-born neonates up until 4 weeks were reported at an incidence of 1.6% with follitropin delta and 1.8% with follitropin alfa (−0.2% [95% CI: −1.9%; 1.5%]). Conclusions Based on comparative trials, the pregnancy and neonatal outcomes from fresh and frozen cycles provide reassuring data on the efficacy and safety of follitropin delta. Trial registration ClinicalTrials.gov Identifier: NCT01956110 registered on 8 October 2013; NCT01956123 registered on 8 October 2013.

Sign in / Sign up

Export Citation Format

Share Document